fundvisualizer.com

Loncar China BioPharma ETFCHNA

Performance (before sales charge)

As of 02/28/2023

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. After-sales-charge returns reflect the maximum sales charge applicable to the fund. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

Asset allocation

As of 02/28/2023
Stock
7.44%
Non-U.S. Stock
92.54%
Bond
0.00%
Non-U.S. Bond
0.00%
Preferred
0.00%
Convertible
0.00%
Cash
0.02%
Other
0.00%

Due to rounding, percentages may not equal 100%.

Sectors

As of 02/28/2023

Basic materials

0.00%

Consumer cyclical

0.00%

Financial services

0.00%

Real estate

0.00%

Consumer defensive

0.00%

Health care

99.98%

Utilities

0.00%

Communication services

0.00%

Energy

0.00%

Industrials

0.00%

Technology

0.00%

Top 10 holdings

As of 02/28/2023

CSPC Pharmaceutical Group Ltd
2.29%
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
2.23%
BeiGene Ltd ADR
2.16%
Sino Biopharmaceutical Ltd
2.14%
Hansoh Pharmaceutical Group Co Ltd
2.12%
Hangzhou Tigermed Consulting Co Ltd Class H
2.11%
Wuxi AppTec Co Ltd
2.06%
WuXi Biologics (Cayman) Inc
2.00%
Pharmaron Beijing Co Ltd Ordinary Shares - Class H
1.94%
Sinopharm Group Co Ltd
1.87%
Fund assets

$5.76 Million

Share class

--

Morningstar category

China Region

Expense ratio

0.79%

Investment objective

Specialty - Health

Documents